Zoonotic Disease Treatment Market

Zoonotic Disease Treatment Market Analysis

The Zoonotic Disease Treatment Market size is estimated at USD 35.37 billion in 2025, and is expected to reach USD 47.11 billion by 2030, at a CAGR of 5.9% during the forecast period (2025-2030).

Factors such as the increasing incidence of zoonotic diseases, increased demand for animal proteins/ consumption of animals, and increasing investment in research and development activities are expected to drive the market's growth over the forecast period.

The market for zoonotic disease treatments is expanding, driven by the rising incidence of diseases like rabies, malaria, and avian influenza. For example, a June 2023 report from Frontiers in Microbiology highlighted that zoonotic diseases impact over 2.5 billion humans globally each year. Zoonoses, transmitted from vertebrate animals to humans, account for over 60% of recognized human diseases and 75% of emerging infectious diseases.

Moreover, the emergence of zoonotic diseases like the Ebola outbreak in Africa has underscored the urgency for effective treatments and vaccines. In September 2022, Uganda declared an Ebola disease outbreak in the country. It was the country’s first Sudan ebolavirus outbreak in a decade. In total, during this outbreak, there were 164 cases (142 confirmed and twenty-two probable), fifty-five confirmed deaths, and eighty-seven recovered patients.

Additionally, the rise in research and developmental activities in the zoonotic diseases market is also boosting its growth. For instance, in August 2023, Merck announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for ERVEBO, which is indicated for preventing disease caused by Zaire ebolavirus in individuals 12 months of age and older.

Therefore, owing to the factors mentioned above, such as the increasing incidence of zoonotic diseases and the rise in research and developmental activities, are expected to drive the growth of the zoonotic disease treatment market.

However, a lack of awareness about the spread of zoonotic diseases in the general population is restraining the growth of the market.

Zoonotic Disease Treatment Market Trends

Malaria Segment is Expected to Witness a Significant Growth Over the Forecast Period

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female, anopheles’ mosquitoes. Some population groups are at considerably higher risk of contracting malaria and developing severe diseases than others. These include infants, children of age 5 years or under, pregnant women, and patients with HIV/AIDS, as well as non-immune migrants, mobile populations, and travelers.

For instance, according to a report published by the Lancet Microbe Journal in January 2024, noted that an estimated 249 million cases of malaria occurred in 85 malaria-endemic countries in 2022, a case incidence of 58 per 1000 population risk. Of the 249 million cases noted in 2022, 233 million (around 94%) were in the WHO African Region, with Nigeria (27%), the Democratic Republic of the Congo (12%), Uganda (5%), and Mozambique (4%), accounting for nearly 50% of all cases.

Similarly, according to a report published by the Our World in Data report in February 2024, the incidence of malaria per thousand people was highest in countries like Benin, Burkina Faso, and Liberia, with 383.45, 376.77, and 356.69, respectively. Therefore, the rising cases of malaria in underdeveloped and developing countries are expected to propel the growth of the malaria segment during the forecast period.

Moreover, clinical advancements in the malaria segment are propelling the growth of the market. For instance, in April 2024, Novartis and Medicines for Malaria Venture (MMV) released positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety.

Thus, the factors above, such as the increasing prevalence of malaria and the growing demand for technological advancements, will likely contribute to the segment's growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America is expected to dominate the market owing to factors such as the region’s advanced healthcare infrastructure, disease burden, regulatory influence, and commitment to technological innovation. North America is equipped high level of healthcare infrastructure and medical research capabilities. The region has advanced healthcare systems, top-tier research institutions, and a well-established pharmaceutical and biotechnology industry. Major companies in zoonotic disease treatment market such as CSL Behring, Johnson & Johnson, Merck, Sanofi, and Zoetis Services LLC are present in the region. These resources enable North America to lead in zoonotic disease research, diagnosis, and treatment. Justifiably, this advanced infrastructure attracts significant investments, both public and private, which contribute to the development of effective treatments and vaccines.

Moreover, the region has experienced a substantial burden of zoonotic diseases, including Lyme disease, West Nile virus, and various foodborne illnesses. According to the research paper “Ecology and Epidemiology of Lyme Disease in Western North America” published by MDPI in 2023, Lyme disease affects about half a million Americans every year, and cases in Canada are rising.

Furthermore, data from the United States Department of Health & Human Services in November 2023 reveals that 60% of diagnosed infectious diseases in the United States are zoonotic. This pronounced disease burden amplifies the demand for effective treatments, emphasizing the market's significance. Additionally, North America's closeness to countries grappling with zoonotic challenges, like rabies, underscores the urgency for comprehensive treatment strategies.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Zoonotic Disease Treatment Industry Overview

The Zoonotic Disease Treatment market is moderately fragmented in nature due to the presence of a several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known that includes Bayer AG, Boehringer Ingelheim International GmbH, CSL Behring, Johnson & Johnson, Merck, Sanofi US, Serum Institute of India, Sun Pharmaceutical Industries Ltd., Vetoquinol, Virbac, Zoetis Services LLC, and Zydus Group, among others.

Zoonotic Disease Treatment Market Leaders

Zoonotic Disease Treatment Market News

• April 2024: Boehringer Ingelheim, launched its NexGard SPECTRA (afoxolaner and milbemycin oxime) in India, following its approval by the Central Drugs Standard Control Organization (CDSCO)
• February 2024: International Union for Conservation of Nature launched a EUR 11 million (USD 15.21 million) initiative, called “One Health in Central Asia in Central Asia at the 14th Meeting of the Conference of the Parties to the Convention on the Conservation of Migratory Species of Wild Animals to combat zoonotic diseases, in Uzbekistan.